Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CGI1746 |
| Synonyms | |
| Therapy Description |
CGI1746 binds to BTK and prevents its activation, resulting in decreased proliferation of B-cells (PMID: 21113169, PMID: 31234030, PMID: 28915637). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CGI1746 | CGI-1746 | BTK inhibitor 39 | CGI1746 binds to BTK and prevents its activation, resulting in decreased proliferation of B-cells (PMID: 21113169, PMID: 31234030, PMID: 28915637). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK T474I BTK C481S | Advanced Solid Tumor | predicted - resistant | CGI1746 | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with CGI1746 failed to inhibit Btk activity in a cell line expressing BTK variants T474I and C481S in culture (PMID: 33526860). | 33526860 |
| BTK T474M BTK C481S | Advanced Solid Tumor | predicted - resistant | CGI1746 | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with CGI1746 failed to inhibit Btk activity in a cell line expressing BTK variants T474M and C481S in culture (PMID: 33526860). | 33526860 |
| BTK T474M BTK C481T | Advanced Solid Tumor | predicted - resistant | CGI1746 | Preclinical - Biochemical | Actionable | In a preclinical study, treatment with CGI1746 failed to inhibit Btk activity in a cell line expressing BTK variants T474M and C481T in culture (PMID: 33526860). | 33526860 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|